カテゴリー： QYResearch, 世界, 医療/バイオ

世界の不安障害・うつ病治療薬市場インサイト及び予測（不安障害治療薬、うつ病治療薬）

◆英語タイトル：Global Anxiety and Depression Treatment Market Insights, Forecast to 2028
	◆商品コード：QY22JLX09224 ◆発行会社（リサーチ会社）：QYResearch ◆発行日：2022年7月（※2025年版があります。お問い合わせください。） ◆ページ数：111 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後3営業日） ◆調査対象地域：グローバル ◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD4,900 ⇒換算￥744,800	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD7,350 ⇒換算￥1,117,200	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD9,800 ⇒換算￥1,489,600	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、不安障害・うつ病治療薬のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に不安障害・うつ病治療薬の世界市場のxxx％を占める「不安障害治療薬」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
不安障害・うつ病治療薬の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの不安障害・うつ病治療薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

不安障害・うつ病治療薬のグローバル主要企業には、Novartis AG、Pfizer Inc.、Bristol-Myers Squibb Company、Johnson & Johnson、Merck、AbbVie、Eli Lilly and Company、GlaxoSmithKline、Sanofi、H. Lundbeck、Mylan、Cipla、Glenmark Life Sciences、Lupin Limited、Amneal Pharmaceuticals、AstraZeneca、Sun Pharmaceutical Industries Ltd.、Intas Pharmaceuticals、Sumitomo Dainippon Pharmaなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

不安障害・うつ病治療薬市場は、種類と用途によって区分されます。世界の不安障害・うつ病治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
不安障害治療薬、うつ病治療薬

【用途別セグメント】
病院、クリニック、薬局、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 不安障害・うつ病治療薬製品概要
- 種類別市場（不安障害治療薬、うつ病治療薬）
- 用途別市場（病院、クリニック、薬局、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界の不安障害・うつ病治療薬販売量予測2017-2028
- 世界の不安障害・うつ病治療薬売上予測2017-2028
- 不安障害・うつ病治療薬の地域別販売量
- 不安障害・うつ病治療薬の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別不安障害・うつ病治療薬販売量
- 主要メーカー別不安障害・うつ病治療薬売上
- 主要メーカー別不安障害・うつ病治療薬価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（不安障害治療薬、うつ病治療薬）
- 不安障害・うつ病治療薬の種類別販売量
- 不安障害・うつ病治療薬の種類別売上
- 不安障害・うつ病治療薬の種類別価格
・用途別市場規模（病院、クリニック、薬局、その他）
- 不安障害・うつ病治療薬の用途別販売量
- 不安障害・うつ病治療薬の用途別売上
- 不安障害・うつ病治療薬の用途別価格
・北米市場
- 北米の不安障害・うつ病治療薬市場規模（種類別、用途別）
- 主要国別の不安障害・うつ病治療薬市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの不安障害・うつ病治療薬市場規模（種類別、用途別）
- 主要国別の不安障害・うつ病治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の不安障害・うつ病治療薬市場規模（種類別、用途別）
- 主要国別の不安障害・うつ病治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の不安障害・うつ病治療薬市場規模（種類別、用途別）
- 主要国別の不安障害・うつ病治療薬市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの不安障害・うつ病治療薬市場規模（種類別、用途別）
- 主要国別の不安障害・うつ病治療薬市場規模（トルコ、サウジアラビア）
・企業情報
Novartis AG、Pfizer Inc.、Bristol-Myers Squibb Company、Johnson & Johnson、Merck、AbbVie、Eli Lilly and Company、GlaxoSmithKline、Sanofi、H. Lundbeck、Mylan、Cipla、Glenmark Life Sciences、Lupin Limited、Amneal Pharmaceuticals、AstraZeneca、Sun Pharmaceutical Industries Ltd.、Intas Pharmaceuticals、Sumitomo Dainippon Pharma
・産業チェーン及び販売チャネル分析
- 不安障害・うつ病治療薬の産業チェーン分析
- 不安障害・うつ病治療薬の原材料
- 不安障害・うつ病治療薬の生産プロセス
- 不安障害・うつ病治療薬の販売及びマーケティング
- 不安障害・うつ病治療薬の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 不安障害・うつ病治療薬の産業動向
- 不安障害・うつ病治療薬のマーケットドライバー
- 不安障害・うつ病治療薬の課題
- 不安障害・うつ病治療薬の阻害要因
・主な調査結果

Market Analysis and Insights: Global Anxiety and Depression Treatment Market
The global Anxiety and Depression Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Anxiety Drugs accounting for % of the Anxiety and Depression Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Anxiety and Depression Treatment market size is valued at US$ million in 2021, while the North America and Europe Anxiety and Depression Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Anxiety and Depression Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Anxiety and Depression Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Anxiety and Depression Treatment market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Anxiety and Depression Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Anxiety and Depression Treatment market.
Global Anxiety and Depression Treatment Scope and Market Size
Anxiety and Depression Treatment market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Anxiety and Depression Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Anxiety Drugs
Depression Drugs
Segment by Application
Hospital
Clinic
Pharmacy
Others
By Company
Novartis AG
Pfizer Inc.
Bristol-Myers Squibb Company
Johnson & Johnson
Merck
AbbVie
Eli Lilly and Company
GlaxoSmithKline
Sanofi
H. Lundbeck
Mylan
Cipla
Glenmark Life Sciences
Lupin Limited
Amneal Pharmaceuticals
AstraZeneca
Sun Pharmaceutical Industries Ltd.
Intas Pharmaceuticals
Sumitomo Dainippon Pharma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anxiety and Depression Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Anxiety Drugs
1.2.3 Depression Drugs
1.3 Market by Application
1.3.1 Global Anxiety and Depression Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Pharmacy
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Anxiety and Depression Treatment Market Perspective (2017-2028)
2.2 Anxiety and Depression Treatment Growth Trends by Region
2.2.1 Anxiety and Depression Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Anxiety and Depression Treatment Historic Market Size by Region (2017-2022)
2.2.3 Anxiety and Depression Treatment Forecasted Market Size by Region (2023-2028)
2.3 Anxiety and Depression Treatment Market Dynamics
2.3.1 Anxiety and Depression Treatment Industry Trends
2.3.2 Anxiety and Depression Treatment Market Drivers
2.3.3 Anxiety and Depression Treatment Market Challenges
2.3.4 Anxiety and Depression Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anxiety and Depression Treatment Players by Revenue
3.1.1 Global Top Anxiety and Depression Treatment Players by Revenue (2017-2022)
3.1.2 Global Anxiety and Depression Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Anxiety and Depression Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Anxiety and Depression Treatment Revenue
3.4 Global Anxiety and Depression Treatment Market Concentration Ratio
3.4.1 Global Anxiety and Depression Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anxiety and Depression Treatment Revenue in 2021
3.5 Anxiety and Depression Treatment Key Players Head office and Area Served
3.6 Key Players Anxiety and Depression Treatment Product Solution and Service
3.7 Date of Enter into Anxiety and Depression Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anxiety and Depression Treatment Breakdown Data by Type
4.1 Global Anxiety and Depression Treatment Historic Market Size by Type (2017-2022)
4.2 Global Anxiety and Depression Treatment Forecasted Market Size by Type (2023-2028)
5 Anxiety and Depression Treatment Breakdown Data by Application
5.1 Global Anxiety and Depression Treatment Historic Market Size by Application (2017-2022)
5.2 Global Anxiety and Depression Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Anxiety and Depression Treatment Market Size (2017-2028)
6.2 North America Anxiety and Depression Treatment Market Size by Type
6.2.1 North America Anxiety and Depression Treatment Market Size by Type (2017-2022)
6.2.2 North America Anxiety and Depression Treatment Market Size by Type (2023-2028)
6.2.3 North America Anxiety and Depression Treatment Market Share by Type (2017-2028)
6.3 North America Anxiety and Depression Treatment Market Size by Application
6.3.1 North America Anxiety and Depression Treatment Market Size by Application (2017-2022)
6.3.2 North America Anxiety and Depression Treatment Market Size by Application (2023-2028)
6.3.3 North America Anxiety and Depression Treatment Market Share by Application (2017-2028)
6.4 North America Anxiety and Depression Treatment Market Size by Country
6.4.1 North America Anxiety and Depression Treatment Market Size by Country (2017-2022)
6.4.2 North America Anxiety and Depression Treatment Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Anxiety and Depression Treatment Market Size (2017-2028)
7.2 Europe Anxiety and Depression Treatment Market Size by Type
7.2.1 Europe Anxiety and Depression Treatment Market Size by Type (2017-2022)
7.2.2 Europe Anxiety and Depression Treatment Market Size by Type (2023-2028)
7.2.3 Europe Anxiety and Depression Treatment Market Share by Type (2017-2028)
7.3 Europe Anxiety and Depression Treatment Market Size by Application
7.3.1 Europe Anxiety and Depression Treatment Market Size by Application (2017-2022)
7.3.2 Europe Anxiety and Depression Treatment Market Size by Application (2023-2028)
7.3.3 Europe Anxiety and Depression Treatment Market Share by Application (2017-2028)
7.4 Europe Anxiety and Depression Treatment Market Size by Country
7.4.1 Europe Anxiety and Depression Treatment Market Size by Country (2017-2022)
7.4.2 Europe Anxiety and Depression Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anxiety and Depression Treatment Market Size (2017-2028)
8.2 Asia-Pacific Anxiety and Depression Treatment Market Size by Type
8.2.1 Asia-Pacific Anxiety and Depression Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Anxiety and Depression Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Anxiety and Depression Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Anxiety and Depression Treatment Market Size by Application
8.3.1 Asia-Pacific Anxiety and Depression Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Anxiety and Depression Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Anxiety and Depression Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Anxiety and Depression Treatment Market Size by Region
8.4.1 Asia-Pacific Anxiety and Depression Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Anxiety and Depression Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Anxiety and Depression Treatment Market Size (2017-2028)
9.2 Latin America Anxiety and Depression Treatment Market Size by Type
9.2.1 Latin America Anxiety and Depression Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Anxiety and Depression Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Anxiety and Depression Treatment Market Share by Type (2017-2028)
9.3 Latin America Anxiety and Depression Treatment Market Size by Application
9.3.1 Latin America Anxiety and Depression Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Anxiety and Depression Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Anxiety and Depression Treatment Market Share by Application (2017-2028)
9.4 Latin America Anxiety and Depression Treatment Market Size by Country
9.4.1 Latin America Anxiety and Depression Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Anxiety and Depression Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anxiety and Depression Treatment Market Size (2017-2028)
10.2 Middle East & Africa Anxiety and Depression Treatment Market Size by Type
10.2.1 Middle East & Africa Anxiety and Depression Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Anxiety and Depression Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Anxiety and Depression Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Anxiety and Depression Treatment Market Size by Application
10.3.1 Middle East & Africa Anxiety and Depression Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Anxiety and Depression Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Anxiety and Depression Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Anxiety and Depression Treatment Market Size by Country
10.4.1 Middle East & Africa Anxiety and Depression Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Anxiety and Depression Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Novartis AG
11.1.1 Novartis AG Company Details
11.1.2 Novartis AG Business Overview
11.1.3 Novartis AG Anxiety and Depression Treatment Introduction
11.1.4 Novartis AG Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.1.5 Novartis AG Recent Developments
11.2 Pfizer Inc.
11.2.1 Pfizer Inc. Company Details
11.2.2 Pfizer Inc. Business Overview
11.2.3 Pfizer Inc. Anxiety and Depression Treatment Introduction
11.2.4 Pfizer Inc. Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.2.5 Pfizer Inc. Recent Developments
11.3 Bristol-Myers Squibb Company
11.3.1 Bristol-Myers Squibb Company Company Details
11.3.2 Bristol-Myers Squibb Company Business Overview
11.3.3 Bristol-Myers Squibb Company Anxiety and Depression Treatment Introduction
11.3.4 Bristol-Myers Squibb Company Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.3.5 Bristol-Myers Squibb Company Recent Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Anxiety and Depression Treatment Introduction
11.4.4 Johnson & Johnson Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.4.5 Johnson & Johnson Recent Developments
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Anxiety and Depression Treatment Introduction
11.5.4 Merck Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.5.5 Merck Recent Developments
11.6 AbbVie
11.6.1 AbbVie Company Details
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Anxiety and Depression Treatment Introduction
11.6.4 AbbVie Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.6.5 AbbVie Recent Developments
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Company Details
11.7.2 Eli Lilly and Company Business Overview
11.7.3 Eli Lilly and Company Anxiety and Depression Treatment Introduction
11.7.4 Eli Lilly and Company Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.7.5 Eli Lilly and Company Recent Developments
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Details
11.8.2 GlaxoSmithKline Business Overview
11.8.3 GlaxoSmithKline Anxiety and Depression Treatment Introduction
11.8.4 GlaxoSmithKline Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.8.5 GlaxoSmithKline Recent Developments
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Anxiety and Depression Treatment Introduction
11.9.4 Sanofi Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.9.5 Sanofi Recent Developments
11.10 H. Lundbeck
11.10.1 H. Lundbeck Company Details
11.10.2 H. Lundbeck Business Overview
11.10.3 H. Lundbeck Anxiety and Depression Treatment Introduction
11.10.4 H. Lundbeck Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.10.5 H. Lundbeck Recent Developments
11.11 Mylan
11.11.1 Mylan Company Details
11.11.2 Mylan Business Overview
11.11.3 Mylan Anxiety and Depression Treatment Introduction
11.11.4 Mylan Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.11.5 Mylan Recent Developments
11.12 Cipla
11.12.1 Cipla Company Details
11.12.2 Cipla Business Overview
11.12.3 Cipla Anxiety and Depression Treatment Introduction
11.12.4 Cipla Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.12.5 Cipla Recent Developments
11.13 Glenmark Life Sciences
11.13.1 Glenmark Life Sciences Company Details
11.13.2 Glenmark Life Sciences Business Overview
11.13.3 Glenmark Life Sciences Anxiety and Depression Treatment Introduction
11.13.4 Glenmark Life Sciences Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.13.5 Glenmark Life Sciences Recent Developments
11.14 Lupin Limited
11.14.1 Lupin Limited Company Details
11.14.2 Lupin Limited Business Overview
11.14.3 Lupin Limited Anxiety and Depression Treatment Introduction
11.14.4 Lupin Limited Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.14.5 Lupin Limited Recent Developments
11.15 Amneal Pharmaceuticals
11.15.1 Amneal Pharmaceuticals Company Details
11.15.2 Amneal Pharmaceuticals Business Overview
11.15.3 Amneal Pharmaceuticals Anxiety and Depression Treatment Introduction
11.15.4 Amneal Pharmaceuticals Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.15.5 Amneal Pharmaceuticals Recent Developments
11.16 AstraZeneca
11.16.1 AstraZeneca Company Details
11.16.2 AstraZeneca Business Overview
11.16.3 AstraZeneca Anxiety and Depression Treatment Introduction
11.16.4 AstraZeneca Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.16.5 AstraZeneca Recent Developments
11.17 Sun Pharmaceutical Industries Ltd.
11.17.1 Sun Pharmaceutical Industries Ltd. Company Details
11.17.2 Sun Pharmaceutical Industries Ltd. Business Overview
11.17.3 Sun Pharmaceutical Industries Ltd. Anxiety and Depression Treatment Introduction
11.17.4 Sun Pharmaceutical Industries Ltd. Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.17.5 Sun Pharmaceutical Industries Ltd. Recent Developments
11.18 Intas Pharmaceuticals
11.18.1 Intas Pharmaceuticals Company Details
11.18.2 Intas Pharmaceuticals Business Overview
11.18.3 Intas Pharmaceuticals Anxiety and Depression Treatment Introduction
11.18.4 Intas Pharmaceuticals Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.18.5 Intas Pharmaceuticals Recent Developments
11.19 Sumitomo Dainippon Pharma
11.19.1 Sumitomo Dainippon Pharma Company Details
11.19.2 Sumitomo Dainippon Pharma Business Overview
11.19.3 Sumitomo Dainippon Pharma Anxiety and Depression Treatment Introduction
11.19.4 Sumitomo Dainippon Pharma Revenue in Anxiety and Depression Treatment Business (2017-2022)
11.19.5 Sumitomo Dainippon Pharma Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の不安障害・うつ病治療薬市場インサイト及び予測（不安障害治療薬、うつ病治療薬）(Global Anxiety and Depression Treatment Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界の不安障害・うつ病治療薬市場インサイト及び予測（不安障害治療薬、うつ病治療薬）

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp